Based on ClinicalTrials.gov in 2017, a clinical phase II study of ETB for the treatment of complicated urinary tract infection and complicated intra-abdominal infection was terminated due to the rapid emergence of drug resistance during treatment [41]. Here, EDNRB is linked to urinary tract infection.